BCRXHealthcare · Drug Manufacturers - Specialty & GenericThe 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +109.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores BioCryst Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BCRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +109.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | JP Morgan | Maintains | Neutral | $12 → $13 |
| 10 Sept 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 10 Sept 2026 | RBC Capital | Downgrade | Sector Perform | $13 → $11 |
| 8 Sept 2026 | Needham | Reiterates | Buy | — |
| 8 Sept 2026 | Needham | Reiterates | Buy | $16 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $14 → $13 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $21 → $20 |
| 13 July 2026 | JP Morgan | Reinstates | Neutral | $12 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $13 → $14 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 30 June 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 30 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 May 2026 | Citizens | Maintains | Market Outperform | — |
| 7 May 2026 | Wedbush | Maintains | Outperform | — |
| 6 May 2026 | Needham | Maintains | Buy | — |
| 30 Jan 2026 | RBC Capital | Maintains | Outperform | — |
| 15 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Nov 2025 | Citizens | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BCRX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, BioCryst Pharmaceuticals, Inc. returned +10.8% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 63% of US stocks
Cheaper than 50% of US stocks
Cheaper than 96% of US stocks
Cheaper than 52% of US stocks
Higher than 80% of US stocks
Higher than 98% of US stocks
Higher than 99% of US stocks
Higher than 94% of US stocks
Higher than 11% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioCryst Pharmaceuticals, Inc. has a market value of $2.0B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $940.6M. The latest quarter grew 33.6% year on year.
Net income over the same four quarters: −$384.7M, a −40.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.50.
Free cash flow in the twelve months to 30 June 2026: $373.4M.
Trailing P/E: 7.0×; forward P/E: 7.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BioCryst Pharmaceuticals, Inc. employs 435 people — $2.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioCryst Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioCryst Pharmaceuticals announced that it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026.
Why it matters — BCRX watchers can note the scheduled date for the company’s third-quarter results.
BioCryst announced that the U.S. FDA approved ORLADEYO 150 mg oral pellets for adults and adolescents with hereditary angioedema (HAE).
Why it matters — The approval expands BioCryst’s portfolio of targeted oral prophylactic therapy options for patients with HAE.
BioCryst Pharmaceuticals announced the formation of a Scientific Advisory Board (SAB) comprising seven scientific and industry leaders with expertise in rare disease research and drug development. The move supports the company's shift toward a more disciplined R&D model centered on external innovation.
Why it matters — A BCRX watcher would care because the new advisory board brings experienced scientific and industry leadership to help guide the company's rare disease pipeline as it evolves toward a more externally focused R&D strategy.
After a recent pullback, BioCryst Pharmaceuticals (NASDAQ:BCRX) bounced off the $8 level and reclaimed its 320-day moving average. Both levels have been key lines of pressure and support for the stock, suggesting multiple layers of technical support are now in place.
Why it matters — BCRX watchers would care because the stock's recovery off the $8 level and its move back above the 320-day moving average point to important technical levels that could inform how the shares behave going forward.
Newly appointed BioCryst Pharmaceuticals CEO Charlie Gayer said at a Morgan Stanley event that the company is shifting its strategy toward external innovation to expand beyond its ORLADEYO hereditary angioedema franchise, targeting a $1 billion rare-disease future.
Why it matters — BCRX watchers would care because the company is signaling a strategic pivot beyond its core ORLADEYO product, which could shape its future growth and pipeline direction.
The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $11 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering BioCryst Pharmaceuticals, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCryst Pharmaceuticals, Inc. 88 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, BioCryst Pharmaceuticals, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +109.9% from the last close, and Ticker Nerd's factor model ranks BioCryst Pharmaceuticals, Inc. 88 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioCryst Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $32 over the next 12 months.
BioCryst Pharmaceuticals, Inc. returned +10.8% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE).
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "BioCryst to Report Third Quarter 2026 Financial Results on November 4". BioCryst Pharmaceuticals announced that it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy used to help prevent HAE attacks, alongside RAPIVAB, an injectable antiviral medicine used in the treatment of influenza in the United States. The company also supports a broader rare-disease pipeline built around oral small-molecule and protein-based therapeutics designed to address difficult-to-treat conditions. BioCryst Pharmaceuticals serves patients, physicians, and healthcare systems through specialty pharmaceutical products aimed at chronic disease management and acute treatment needs. Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals plays a focused role in the rare-disease market by combining commercial medicines with targeted drug development expertise.
CEO Mr. Charles K. Gayer · 435 employees · United States · https://www.biocryst.com
